The Influence of Exemestane on the Lipid Profile in Breast Cancer Patients: A Meta-Analysis and Systematic Review of Randomized Controlled Trials
Wei‐Yuan Huang,
No information about this author
Meiwen Zhang,
No information about this author
Dongmei Gao
No information about this author
et al.
Hormone and Metabolic Research,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 17, 2025
Abstract
Controversial
results
exist
regarding
the
influence
of
exemestane
on
serum
lipids
in
women
affected
with
breast
cancer.
Since
CVD
remains
predominate
cause
demise
cancer
and
considering
long-term
use
cancer,
this
meta-analysis
holds
significant
value.
Hence,
we
carried
out
current
randomized
controlled
trials
(RCTs)
to
evaluate
impact
treatment
lipid
parameters
PubMed/Medline,
Web
Science,
EMBASE,
Scopus
databases
were
explored
for
articles
published
from
inception
till
December
3,
2024.
A
random
effect
analysis
was
employed
result
generation
as
weighted
mean
differences
(WMD)
95%
confidence
intervals
(CI).
Six
eligible
relevant
RCTs
incorporated
meta-analysis.
The
comprehensive
findings
indicated
a
reduction
TC
(WMD:
–8.13
mg/dl,
CI:
–14.48
–1.79,
p=0.012),
HDL-C
–6.60
mg/dl;
–8.17
–5.01,
p<0.001)
an
increase
LDL-C
4.66
0.26
9.06,
p=0.038)
after
intervention.
Additionally,
noteworthy
decline
levels
TG
noted
studies
lasting
less
than
12
months
duration
–16.18
–25.99
–6.37,
p=0.001).
Exemestane
influences
It
elevates
while
decreasing
TC,
TG,
concentrations.
Language: Английский
Risk factors for breast cancer recurrence in postmenopausal women: a bibliometric study
Frontiers in Oncology,
Journal Year:
2025,
Volume and Issue:
15
Published: April 1, 2025
Breast
cancer
is
a
significant
healthcare
challenge,
and
despite
advancements
in
treatment,
the
risk
of
recurrence
remains
critical
concern,
particularly
for
postmenopausal
women.
Understanding
factors
that
contribute
to
this
essential
improving
monitoring
prevention
strategies,
ultimately
enhancing
long-term
care
disease
management
patient
population.
The
study
analyzes
scholarly
literature
on
patterns
Caucasian
women
with
prior
breast
cancer,
highlighting
potential
innovative
insights
reduce
mortality
improve
survival.
We
used
R
software
"R-Bibliometrix"
package
analyze
recurrence.
Data
was
collected
from
Web
Science
Core
Collection
database
identify
relevant
documents
highlight
collaborative
efforts
commonly
terminology.
extensive
analysis
included
500
articles
authored
by
3,204
individuals
195
distinct
sources,
all
published
between
2010
2024.
It
specifically
focused
assessing
results
underscored
several
influencing
recurrence,
encompassing
hormonal
factors,
lifestyle
influences,
effectiveness
various
types
adjuvant
therapy,
role
genetic
factors.
In
conclusion,
research
highlights
multifaceted
nature
contributing
believe
not
only
enhances
current
understanding
but
also
provides
clear
directions
future
improvements
clinical
practice
health
policy.
Language: Английский
Aromatase inhibitors versus tamoxifen: serum biochemical profile and imaging studies in Latin American women with ER+ breast cancer
Cuadernos de Educación y Desarrollo,
Journal Year:
2025,
Volume and Issue:
17(4), P. e8139 - e8139
Published: April 24, 2025
The
estimated
global
incidence
of
new
breast
cancer
cases
is
2.26
million,
and
75%
these
are
estrogen
receptor
positive
(ER+).
Treatment
involves
the
use
tamoxifen
(TX)
or
aromatase
inhibitors
(AIs),
such
as
anastrozole
letrozole.
medications
associated
with
changes
in
blood
cholesterol
levels
hepatic
steatosis,
TX
promotes
steatosis
more
than
AIs.
Thus,
aim
this
study
was
to
determine
effect
AIs
on
biochemical
markers
women
ER+
cancer.
A
cross-sectional
performed
between
2021
2024
comprising
38
who
received
a
public
hospital
Brazil.
Primary
data
were
collected
through
interviews
secondary
obtained
medical
records,
including
count,
lipid
profile,
liver
ultrasound
(US)
results.
Of
34
cancer,
mean
age
56.67
±
12.38
years,
those
used
had
higher
LDL
(Low-density
lipoprotein)
(p
<
0.001),
MCV
(Mean
corpuscular
volume)
=
0.033),
NEU
(Segmented
neutrophils)
0.044),
ALP
(Alkaline
phosphatase)
0.019)
values
Group,
all
throughout
treatment.
at
baseline
based
US
no
after
Our
results
suggest
that
adjuvant
therapy
for
not
an
increase
enzymes,
exception
ALP,
development
steatosis.
However,
Ais
increased
values,
fact
should
be
considered
when
choosing
treatment,
especially
risk
factors,
diabetes
mellitus
(DM),
obesity,
dyslipidemia.
Language: Английский
Statins and prognosis of female breast cancer: a meta-analysis
Clinical & Translational Oncology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 26, 2025
Language: Английский
Benzimidazole‐Containing Compounds as Anticancer Agents
ChemistrySelect,
Journal Year:
2024,
Volume and Issue:
9(32)
Published: Aug. 22, 2024
Abstract
Cancer
is
the
second
leading
cause
of
death
today
and
remains
a
threat
to
human
health.
The
advent
multi‐drug
resistance
adverse
effects
make
current
first‐line
anti‐cancer
medicines
inadequate,
despite
fact
that
numerous
efforts
have
been
made
in
field
cancer
therapy
significant
progress
has
diagnosis
treatment
cancer.
Consequently,
development
novel
anticancer
drugs
with
high
activity
minimal
toxicity
imperative.
benzimidazole
ring
attracted
attention
medicinal
chemists
due
its
pharmacological
properties.
heterocyclic
pharmacophore
crucial
scaffold
for
developing
pharmaceuticals
drugs.
In
this
review,
we
summarized
recent
as
privileged
discovery
agents
based
on
biological
targets,
such
VEGFR
(Vascular
Endothelial
Growth
Factor),
PI3
K
inhibitors
(Phosphoinositide
3‐kinase),
EGFR
kinase
(Epidermal
Factor
Receptor),
PARPs
(Poly
ADP‐ribose
polymerases),
Tubulin
Polymerization,
HAT/HDAC
(histone
acetylase/histone
deacetylase),
SphK1
(Sphingosine
kinase‐1
inhibitors),
aromatase,
carbonic
anhydrase,
topoisomerase
inhibitors.
last
5
years
literature
reviewed
relevant
studies
review.
Language: Английский
In Silico Discovery of Multi-Target Natural Ligands and Efficient siRNA Design for Overcoming Drug Resistance in Breast Cancer via Local Therapy
Seyed Mohammad Javad Hashemi,
No information about this author
Ali Barzegar,
No information about this author
Javad Akhtari
No information about this author
et al.
bioRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 11, 2024
Abstract
In
this
study,
we
designed
an
efficient
siRNA
for
PKMYT1
gene
knockdown,
and
evaluated
the
binding
affinities
of
different
natural
ligands
to
crucial
proteins
involved
in
breast
cancer.
Designed
showed
strong
affinity
minimal
off-target
effects.
Molecular
docking
studies
identified
new
as
antagonists
with
high
aromatase,
estrogen
receptor
alpha,
HER2,
PARP10,
well
agonists
MT2
STING.
The
ligand
SCHEMBL7562664
was
introduced
a
golden
due
its
among
multiple
targets
lack
cytotoxic
mutagenic
Natural
small
molecules
research,
their
multi-target
characteristics,
provided
solution
overcome
problem
drug
resistance
cancer
cells.
Furthermore,
proposed
three
dimensional
scaffold
design
local
therapy
offers
promising
approach
increase
delivery
efficacy
these
molecules,
reduce
systemic
side
effects,
improve
treatment
outcomes.
significant
favorable
pharmacokinetic
properties
were
identified,
which
paves
way
further
research
targeted
Language: Английский